I wonder if the partial success rate of Rituximab might be linked to the persistent viral theory.
Rituximab is B cell depleting. We know that B cells can harbor Epstein Barr Virus. We know that often the classic onset for CFS is after a bout of infectious mono.
Conveniently for EBV - B cells can reproduce via clonal division and through that method EBV also spreads to the two daughter cells. I'm guessing this means of EBV disease progression would occur regardless of antiviral activity of Valtrex? Hence Valtrex would be ineffective against a virus that has incorporated itself into the host-cell DNA and is reproducing via a non-lytic pathway?
After all EBV seems to have an association with Multiple Sclerosis but Valtrex is not an effective treatment for MS. But boosting a patients immunity to EBV may be a promising treatment
http://www.msra.org.au/QLD-breakthrough-progressive-ms
So possibly there is some pathological similarities between MS and CFS. In short I'm not sure if we should try and see autoimmunity and persistent viral infections in separate universes. There may be something going on that hasn't been studied closely enough.
So perhaps we need B cell depletion and antiviral activity simultaneously to stop any free-EBV from reinfecting new B cells as they are produced?
Even if this theory was true it would only work for a subset of CFS patients. My serology for instance shows either no or undetectable antibodies to EBV or early EBV antigens which maybe implies I've never had EBV.
So maybe this is something that patients trialling Rituximab can consider. Valtrex is reasonably safe and might be a good idea to take with a B cell depleting drug as it might help your immune system hold back some viruses that are suspected to be a problem in CFS - particularly EBV which specifically targets B cells for infection.
Secondly I think we should be keeping an eye on the antiviral drug DRACO as it progresses and trying to find ways to get a trial started for it. DRACO. Quoting from the below article.
DRACO (Double-stranded RNA Activated Caspase Oligomerizer) is designed to detect cells that have been virally infected and then eradicate only the infected cells, rapidly ending the infection. DRACO has proven effective in vivo against influenza and three hemorrhagic fever viruses, and in vitro against 15 different viruses—including common cold viruses, the H1N1 influenza strain, adenoviruses, a mouse polio virus, dengue fever, and stomach viruses, among others. It has also been tested and proven safe in both mice and 11 different human and animal cell types representing organs like the heart, lungs, liver, and kidney, among others.
http://www.rdmag.com/news/2014/01/new-nanotechnology-traps-viruses-they-infect-host-cells